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elderly. Of these patients, 31% received chemotherapy, 35.5% radiotherapy, and 10% 
both. The proportions of elderly patients receiving chemotherapy, radiation therapy, 
or both, remained stable throughout the study period. The most common indica-
tions for which elderly patients received chemotherapy included gastrointestinal 
(39%), lung (15%), breast (12%), and head and neck (9%) cancers. Overall, 17% of 
the elderly patients received > 2 lines of chemotherapy protocols; a similar rate 
(16%) was observed in the subgroup of patients ≥ 85 years of age. ConClusions: 
Approximately 30% of the cancer population treated in a large tertiary cancer center 
were elderly patients (≥ 75 years of age). The findings of this study may promote a 
discussion regarding medical resources, staff training, and planning a designated 
evaluation for geriatric cancer patients that should include special consideration 
to the patients’ comprehensive functioning.
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objeCtives: To describe systemic treatment of metachronous metastases and 
the reasons of not receiving systemic treatment in patients with breast cancer.  
Methods: Patients diagnosed with breast cancer without metastasis at initial diag-
nosis (M0) between 2006-2008 were selected from the Eindhoven Cancer Registry. 
By means of active follow-up by the Cancer Registry staff until January 2012, data 
on development of metastatic disease, treatment, and reasons of not receiving sys-
temic treatment were collected directly from the patient files. Results: Of 1,382 
patients diagnosed with M0 breast cancer, 116 (8%) developed metachronous metas-
tases during a median follow-up of 4.4 years. Of the patients developing metachro-
nous metastases, 86 (74%) patients received systemic treatment with a median (± 
SD) age of 59.7 (± 13.4) years. Of these, 46 patients (53%) received chemotherapy, 19 
patients (22%) received hormonal therapy and 21 patients (24%) received a combi-
nation of chemotherapy and hormonal therapy. Median (± SD) age of the patients 
who did not receive systemic treatment (n= 30) was 70.0 (± 15.9) years. Of the 67 
patients receiving chemotherapy, 17 patients (25%) were treated with taxane con-
taining chemotherapy as first-line treatment. Of the 30 patients without any sys-
temic treatment, 10 patients received radiotherapy, 3 patients underwent surgery 
and 6 patients refrained from systemic treatment. Other reasons for not receiving 
systemic treatment were: extensiveness of metastases/life expectancy (n= 4), death 
before first application of chemotherapy (n= 4), high age (n= 1), comorbidities (n= 1) or 
bad experience with chemotherapy in the past (n= 1). ConClusions: Of the initially 
M0 breast cancer patients who developed metastases during follow-up the majority 
received systemic treatment. A quarter of the patients did not receive systemic treat-
ment, primarily due to other treatment policies, refraining from treatment or poor 
condition. This study provides more insight into the treatment of metachronous 
metastases in the Netherlands.
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objeCtives: To describe current guidance on BRCA testing practices in patients 
with ovarian cancer (OC) in China, European countries, and US. Methods: 
Guideline databases like National Guideline Clearinghouse, Guidelines 
International Network, and National Institute for Health and Care Excellence 
were searched for guidelines in both ovarian and breast cancer. Additionally, 
relevant medical societies like United States Preventive Services Task Force, 
National Society of Genetic Counselors, American Society of Clinical Oncology, 
European Society for Medical Oncology, European Society of Human Genetics, 
Chinese Society of Clinical Oncology, Chinese Academy of Medical Sciences, and 
International Cancer Genome Consortium were considered. Guidelines were 
included if they contained recommendations for BRCA testing in OC or patient 
characteristics for BRCA mutation in OC, were published after 2003, were cur-
rently valid, and published in English, Chinese or German language. Results: The 
search revealed a total of 22 guidelines. Ten breast cancer guidelines were excluded 
because they did not add any information beyond that found in guidelines for OC. 
Ten out of 12 guidelines recommend genetic testing for healthy individuals with 
familial history of ovarian or breast cancer and a personal history of breast cancer. 
Most guidelines differ in their description of selection criteria such as degree of 
relationship between affected individuals and counselee, age at diagnosis, and 
individual history of early onset cancer. Five out of 12 guidelines also recommend 
screening for patients of Jewish Ashkenazi or Icelandic descent. ConClusions: 
Current guidance recommends genetic testing primarily for healthy individuals; 
a few guidelines recommend testing in diagnosed ovarian cancer patients. Using 
current recommendations a substantial number of patients with OC due to an 
inherited BRCA mutation are missed. With options for treatment aimed at muta-
tion carriers, identification of all OC patients with BRCA mutation will facilitate a 
personalized therapy and identify family members at risk of cancer.
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tive and level of analysis (macro or meso level), and whether regression correction 
should be performed. A limitation of the illustrative case study was that costs of 
sustainability activities were not collected.
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objeCtives: To critically assess cost-sharing schemes between payers and market-
ing authorization holders (MAHs) that are in some jurisdictions used as a means to 
control public spending on prescription drugs. Methods: Cost-sharing scheme can 
be theoretically expressed as the two-step process, where the discount of the MAH 
equals p when x≤ n, and 0 when x> n, where n is the number of weeks/months with 
reduced price of a drug and x is the length of treatment in weeks/months. Within 
such a scheme, the overall discount has no lower limit as it is inversely proportional 
to x, i.e., np/x. Payers and MAHs may estimate and agree upon the expected length 
of treatment x= m0 based on, e.g., randomized clinical trials (RCTs); however, these 
estimates may be unreliable due to, inter alia, market power of MAHs that could 
influence prescribers to select those patients that will remain longer on the treat-
ment. Results: Two-step cost-sharing scheme results in the effective discount that 
is lower than expected discount by (x-m0) /x, once x surpasses m0. The lower limit 
of the discount can be achieved if the two-step cost-sharing scheme is modified 
by an additional step: the discount then equals (i) p when x≤ n, (ii) 0 when m0≥ x> n, 
and (iii) np/m0 when x> m0. Cost-sharing scheme in this format guarantees that the 
effective discount remains at the expected level of np/m0 and gives no incentive 
to MAHs to exert their market power and prolong treatment duration. We applied 
our simple model to a real-life case of innovative oncological drug (p= 100%; n= 6 
weeks; m0= 30 weeks). ConClusions: We have shown that cost-sharing schemes 
should incorporate an additional step in order to ensure the effective control of 
expenditure for drugs. This finding may be of value to those jurisdictions that resort 
to cost-sharing as a tool in curtailing prescription drug costs.
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objeCtives: Limited data regarding effectiveness, efficacy, safety or cost-effective-
ness at marketing authorization reflect uncertainties that payers try to counteract 
with performance-based risk-sharing arrangements (PBRSAs). PBRSAs link medi-
cines’ reimbursement to health outcomes and seem to reduce these uncertainties 
– especially for stratified medicine in oncology. We wanted to identify PBRSAs for 
stratified medicine in oncology to discuss advantages, disadvantages, their cost-
effectiveness and whether they could reduce uncertainties. Methods: A litera-
ture search was conducted in bibliographical databases from 2003-2013. Searching 
websites of reimbursement bodies from Australia, Canada, Germany, UK, USA and 
hand searching completed the search strategy. Publications were eligible if reim-
bursement for stratified medicine in oncology was linked to health outcomes. 
A self-developed checklist based on ISPOR Task Force Report on PBRSAs (Garrison 
et al., [Value Health. 2013; 16 (5): 703-19]) was used to conduct quality assessment. 
This checklist consists of five domains assessing the quality of a PBRSA: descrip-
tion, desirability and rationale, implementation, evidence collection and evalua-
tion. Results: We identified 43 publications resulting in 40 PBRSAs (Canada: 12, 
Italy: 9, UK: 7, Australia: 8, The Netherlands: 2, USA: 1, Slovenia: 1). Most schemes are 
related to leukemia (mainly dasatinib, imatinib and nilotinib). These PBRSAs were 
categorized in subcategories: risk sharing schemes (RSS) such as ‘outcomes guar-
antees’ (n= 7), ‘conditional treatment continuation’ schemes (n= 22), ‘money back 
guarantees’ (n= 3) and coverage with evidence development schemes (CED) such as 
‘only in research’ schemes (n= 8). Quality assessment was limited by lack of reporting 
on PBRSAs’ details. Therefore, ambiguity remains about PBRSAs’ cost-effectiveness 
and their reduction of uncertainties. ConClusions: RSS provide faster access to 
therapies, guarantee reimbursement for manufacturers and possibly cost contain-
ment for payers, but do not necessarily collect additional evidence. The administrative 
burden and related costs appear to be huge. Existing value of information analysis 
approaches were not applied to CED schemes. Evaluations of PBRSAs are necessary 
to assess their value.
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objeCtives: Primary: To describe the use of anti-cancer treatments in elderly 
patients (≥ 75 years of age) at the Davidoff Center between 2006 and 2013. Secondary: 
To investigate the correlations between anti-cancer treatments and socio-demo-
graphic- and cancer-related parameters. Methods: The analysis included all 
elderly (≥ 75 years) cancer patients treated at the Institute of Oncology, Davidoff 
Center between 2006 and 2013. The analysis included Israeli residents (i.e., “medical 
tourists” were excluded). Patients who were treated elsewhere and had a single con-
sultation appointment at the Davidoff Center were also excluded from the analysis. 
The following parameters were assessed: demographic variables, cancer diagnosis, 
chemotherapy and radiation treatments received, clinic visits, hospitalizations, and 
the utilization of other health-related services. Results: Out of 21,009 new patients 
treated at the Davidoff Center between 2006 and 2013, 6, 553 patients (31%) were 
